Lack of Bcl-2 expression in feline follicular lymphomas.

J Vet Diagn Invest

Institut fuer Veterinaer-Pathologie, Justus-Liebig-Universitaet Giessen, Giessen, Hessen, Germany.

Published: November 2019


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Bcl-2, an anti-apoptotic protein, is commonly overexpressed in follicular lymphomas in humans. This is usually the result of a chromosomal translocation that transposes the gene into the immunoglobulin gene locus. The immunohistochemical assessment of this overexpression can be used as a tool for the differentiation of follicular lymphoma and follicular hyperplasia. In cats, little information about the expression of Bcl-2 in follicular lymphoma exists. We investigated 18 follicular lymphomas histologically and immunohistochemically for the expression of Bcl-2, CD3, CD45R, and feline leukemia virus. Clonality was assessed by PCR for antigen receptor gene rearrangements. Although the histology resembled that of their human counterparts, diffuse expression of Bcl-2 within the follicles of the feline lymphomas, as seen in human cases, was not present. Only single cells within the follicles, comparable to the reactive controls, were positive for Bcl-2 expression. The mean survival time of 4.6 y confirmed the indolent character of the tumor. None of the clinical parameters assessed were statistically significant predictors of survival. Furthermore, a statistically significant difference in survival of animals with or without anti-neoplastic therapy was also not demonstrable.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900727PMC
http://dx.doi.org/10.1177/1040638719877916DOI Listing

Publication Analysis

Top Keywords

follicular lymphomas
12
expression bcl-2
12
bcl-2 expression
8
follicular lymphoma
8
follicular
6
expression
5
bcl-2
5
lack bcl-2
4
expression feline
4
feline follicular
4

Similar Publications

Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for up to 12 cycles (28 days/cycle).

View Article and Find Full Text PDF

Obinutuzumab-induced severe acute thrombocytopenia: a case report and literature review.

Front Immunol

September 2025

Department of Haematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Multiple clinical studies have shown that compared with rituximab combined with chemotherapy, obinutuzumab combined with chemotherapy can significantly improve the progression-free survival (PFS) of patients, effectively reduce the risk of disease progression, and improve patient prognosis. The main adverse effects of obinutuzumab include infusion reactions, myelosuppression, infection, cardiotoxicity, tumor lysis syndrome (TLS), etc.

View Article and Find Full Text PDF

An 84-year-old man with a history of amputation and follicular lymphoma developed a non-healing ulcer on his stump, initially diagnosed as a pressure ulcer cause by the clinic and lack of B-symptoms. Despite wound care, the lesion worsened. A biopsy revealed de novo diffuse large B-cell lymphoma (DLBCL), non-germinal center subtype.

View Article and Find Full Text PDF

Obesity has been associated with non-Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, using eight genome-wide association studies of European ancestry (N = 10,629 cases, 9505 controls) and constructing polygenic scores for body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-hip ratio adjusted for BMI (WHRadjBMI). Higher genetically determined BMI was associated with an increased risk of DLBCL [odds ratio (OR) per standard deviation (SD) = 1.

View Article and Find Full Text PDF

Behavioral investigation of reactive and neoplastic lymphocytes in human lymph nodes in 4D.

PLoS One

September 2025

Institute for general pharmacology and toxicology, Goethe University, University Hospital, Frankfurt/Main, Hesse, Germany.

This study deals with a 4D investigation of lymphocytes in human tissue under reactive and neoplastic conditions. The immune system's response to pathogens highly depends on cell interaction and movement, which makes it essential to analyze these dynamics. To achieve this, we observed cells and their movement in 4D.

View Article and Find Full Text PDF